Wednesday, February 14, 2018

Dihydroergotamine antiadrenergic drug and its pharmacology

INTRODUCTION:-
* This compound belongs to the class of organic compounds known as ergotamines, dihydroergotamines and derivatives.
* These are structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.

MECHANISM OF ACTION:-
* Activation of 5-HT1D  located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache .
* 2) Activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.

PHARMACOKINETICS:
* HALF LIFE :- 9  hours.
* PROTEIN BINDING :- 93%
* Volume of distribution :- 800 L


DRUG –DRUG INTERACTIONS-
* ACEPROMAZINE+ DHE= The risk of adverse effects can be increased .
* ACETOPHENAZINE +DHE= adverse effects can be increased.
* APREPITANA+DHE= The serum concentration of DHE can be increased.
* BOCEPRAVIL+ DHE= The serum concentration of DHE can be increased.


SIDE EFFECTS:-
* Drowsiness
* Headache
* Nausea
* Vomiting
* Diarrhoea
* Flushing
* Dizziness

THERAPEUTICS USES:- It works by narrowing the blood vessels around the brain and affects blood flow patterns that are   associated with certain types of headaches. injection is used to treat a migraine or  cluster headache attack.

REFERENCE:-Tripathi K D; "Essential of medical pharmacology";7th edition ;page no-140,175,176,178

No comments:

Post a Comment